Print this page
Forward this page

Novescia is one of France's leading medical biology groups, established in September 2008 and currently comprising over 150 laboratories across the country.

Consolidation ahead

Following the landmark transaction by which Novescia acquired the biology pole of Générale de Santé at the end of 2009, the Company continues to actively participate in the gradual consolidation of the fragmented private lab market in France. The latter is driven by multiple factors, including the compulsory certification of medical labs, an increasing number of biologists nearing retirement age and facing succession issues, continuing cost pressure in the industry, etc. Although still at the beginning of such consolidation phase taking place in France, all signs point in that direction. 

Efficient partnership

Novescia is implementing an ambitious growth strategy consisting of acquiring labs in defined geographical areas in France, and centralising on technical platforms the medical analyses formerly performed within the individual entities. Novescia’s innovative business model comprises a true partnership with biologists and an industrial approach focused on both quality and efficiency of operations.


In July 2010, Cobepa acquired a minority stake of 10% stake in Novescia. In March 2015 Cobepa's stake was sold to Cerba European Lab.

Cobepa S.A.

Cobepa S.A.
Rue de la Chancellerie 2, box 1
1000 Brussels
+ 32 2 213 32 10
+ 32 2 513 17 02

Cobepa North America Inc.

Cobepa North America Inc.
Tower 49
12 East 49th Street
New York, NY 10017
United States
+1 (646) 679 5177

Ibel Beteiligungsberatung GmbH (Member of Cobepa Group)

Ibel Beteiligungsberatung GmbH
Theresienstrasse 1
80333 München
+32 2 213 32 10